196 related articles for article (PubMed ID: 37608391)
1. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
[TBL] [Abstract][Full Text] [Related]
2. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
Kaeley GS; Schett G; Conaghan PG; McGonagle D; Behrens F; Goupille P; Gaillez C; Parikh B; Bakewell C
Rheumatology (Oxford); 2024 Jan; 63(1):41-49. PubMed ID: 37097894
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
4. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.
Helliwell PS; Mease PJ; Kavanaugh A; Coates LC; Ogdie A; Deodhar A; Strand V; Kricorian G; Liu LXH; Collier D; Gladman DD
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35863864
[TBL] [Abstract][Full Text] [Related]
5. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM; Mease PJ; Helliwell PS; FitzGerald O; Fleishaker DL; Mundayat R; Young P
BMC Rheumatol; 2022 Sep; 6(1):68. PubMed ID: 36045453
[TBL] [Abstract][Full Text] [Related]
6. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
8. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
Giles JT; Ogdie A; Gomez Reino JJ; Helliwell P; Germino R; Stockert L; Young P; Joseph W; Mundayat R; Graham D; Ritchlin C
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33452181
[TBL] [Abstract][Full Text] [Related]
9. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2.
Cantini F; Marchesoni A; Novelli L; Gualberti G; Marando F; McDearmon Blondell E; Gao T; McGonagle D; Salvarani C
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38331400
[TBL] [Abstract][Full Text] [Related]
10. Enthesitis indices identify different patients with this characteristic in axial and peripheral spondyloarthritis and also in psoriatic arthritis: ASAS-PerSpA data.
Granados REM; Ladehesa-Pineda ML; Puche-Larrubia MÁ; Escudero-Contreras A; Dougados M; Collantes-Estevez E; López-Medina C
Arthritis Res Ther; 2023 Jun; 25(1):99. PubMed ID: 37291655
[TBL] [Abstract][Full Text] [Related]
11. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
McGonagle D; McInnes IB; Deodhar A; Schett G; Shawi M; Kafka S; Karyekar CS; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Ritchlin CT; Rahman P; Mease PJ
Rheumatology (Oxford); 2021 Nov; 60(11):5337-5350. PubMed ID: 33822898
[TBL] [Abstract][Full Text] [Related]
12. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
[TBL] [Abstract][Full Text] [Related]
16. Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR).
Yang F; Lu C; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X
Chin Med J (Engl); 2023 Apr; 136(8):951-958. PubMed ID: 37036901
[TBL] [Abstract][Full Text] [Related]
17. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
[TBL] [Abstract][Full Text] [Related]
18. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
[TBL] [Abstract][Full Text] [Related]
19. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.
Coates LC; Bushmakin AG; FitzGerald O; Gladman DD; Fallon L; Cappelleri JC; Hsu MA; Helliwell PS
Arthritis Res Ther; 2021 Mar; 23(1):94. PubMed ID: 33766074
[TBL] [Abstract][Full Text] [Related]
20. Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI.
Palominos PE; de Campos APB; Ribeiro SLE; Xavier RM; Xavier JW; de Oliveira FB; Guerra B; Saldanha C; Mancuso ACB; Kohem CL; Gasparin AA; Sampaio-Barros PD
Adv Rheumatol; 2019 Jun; 59(1):23. PubMed ID: 31208465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
